SIA "magnipharma", Pharmaceutical Import Profile — Latvia (DGFT 2022–2026)

Name: SIA "magnipharma", Pharmaceutical Import Records from India — 2 Products, $300.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SIA "magnipharma", — Pharmaceutical Importer Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

SIA "magnipharma",

Pharmaceutical Importer · Latvia · Antiviral & HIV Medications Focus · $300.0K Total Trade · DGFT Verified

SIA "magnipharma", is a pharmaceutical importer based in Latvia with a total trade value of $300.0K across 2 products in 1 therapeutic categories. Based on 6 verified import shipments from Indian Customs (DGFT) records, SIA "magnipharma", is the #1 buyer in 1 product including Velpatasvir. SIA "magnipharma", sources from 1 verified Indian supplier, with Euro Lifecare Private Limited accounting for 100.0% of imports.

SIA "magnipharma", — Import Portfolio & Supplier Network

SIA "magnipharma", import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SIA "magnipharma",?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Euro Lifecare Private Limited	$50.0K	5	100.0%

SIA "magnipharma", sources from 1 verified Indian supplier across 4 distinct formulations. The sourcing is highly concentrated — Euro Lifecare Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does SIA "magnipharma", Import?

Formulation	Value	Ships
Velpanat (sofosbuvir and velpatasvir and400mg/100MG) Film-Coated tablets of 400MG/100 MG; 28 Film-Coated tablets in	$50.0K	2
Mfg :natco pharma limited gst inv no : 362410106413, 362410700624, 362410700625dt: 26.03.2025 gst no	$0	1
Ws sofosbuvir 300MG	$0	1
Ws velpatasvir 300MG	$0	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sofosbuvir	Antiviral & HIV Medications	$150.0K	3	0.4%	2
2	Velpatasvir	Antiviral & HIV Medications	$150.0K	3	0.6%	1

SIA "magnipharma", imports 2 pharmaceutical products across 1 categories into Latvia totaling $300.0K. The company is the #1 buyer for 1 product: Velpatasvir.

SIA "magnipharma", — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SIA "magnipharma" is a Latvian limited liability company (SIA) specializing in the wholesale distribution of pharmaceutical products. Established on December 9, 2004, the company is registered under the number 50003715491. Its legal address is Meistaru iela 8 – 7, Rīga, LV-1050, Latvia. (company.lursoft.lv) The company is owned by a single individual, Aleksandrs Kazačkovs, who also serves as a member of the board. SIA "magnipharma" plays a significant role in Latvia's pharmaceutical distribution network, acting as a primary wholesaler that imports and distributes a range of pharmaceutical products to various healthcare providers across the country.

2Distribution Network

SIA "magnipharma" operates its distribution network from its headquarters located at Meistaru iela 8 – 7, Rīga, LV-1050, Latvia. (company.lursoft.lv) While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's central location in Rīga suggests a strategic position for nationwide distribution. The company is likely to utilize Latvia's well-developed transportation infrastructure, including road, rail, and port facilities, to facilitate the import and distribution of pharmaceutical products both within Latvia and potentially to neighboring countries.

3Industry Role

In Latvia's pharmaceutical supply chain, SIA "magnipharma" functions primarily as a wholesaler. The company imports pharmaceutical products from international suppliers, including India, and distributes them to various healthcare entities such as hospitals, pharmacies, and clinics across Latvia. This role is crucial in ensuring the availability of a diverse range of pharmaceutical products to meet the healthcare needs of the Latvian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SIA "magnipharma",

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SIA "magnipharma" demonstrates a high level of supplier concentration, sourcing its pharmaceutical imports exclusively from EURO LIFECARE PRIVATE LIMITED, an Indian supplier. This single-source dependency indicates a strategic choice to maintain a focused and potentially more manageable supplier relationship. The company's import data reveals a consistent pattern of shipments, suggesting a stable and reliable partnership with EURO LIFECARE PRIVATE LIMITED. However, this concentration also exposes SIA "magnipharma" to risks associated with supply chain disruptions, such as those arising from geopolitical tensions, regulatory changes, or operational issues within the supplier's operations.

2Supply Chain Resilience

The resilience of SIA "magnipharma"'s supply chain is closely tied to its exclusive relationship with EURO LIFECARE PRIVATE LIMITED. While this focused sourcing strategy may streamline operations, it also means that the company has limited backup suppliers to mitigate potential disruptions. The import data indicates a narrow product range, with only two products imported from a single supplier, which could be a strategic decision to ensure quality and consistency. However, this lack of diversification may pose challenges in the event of supply chain disruptions. Additionally, the company must ensure that its supplier complies with international Good Manufacturing Practice (GMP) standards to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into Latvia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Latvia

1Regulatory Authority & Framework

In Latvia, the State Agency of Medicines (Zāļu valsts aģentūra) is the primary regulatory authority overseeing the pharmaceutical sector. The agency is responsible for the registration, import, and distribution of medicinal products within Latvia. Key legislation governing pharmaceutical imports includes the Law on Licensing Procedures for Pharmaceutical Activities, which outlines the requirements for obtaining licenses for the import and distribution of medicinal products. The marketing authorization pathway for Indian generics involves submitting an application to the State Agency of Medicines, accompanied by necessary documentation such as a description of the manufacturing process, therapeutic indications, and results of pharmaceutical and clinical trials.

2Import Licensing & GMP

To import pharmaceutical products into Latvia, companies must obtain an import license from the State Agency of Medicines. This license authorizes the holder to import specific medicinal products into the country. Additionally, the imported products must comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. SIA "magnipharma" holds a wholesale distribution authorization, allowing it to distribute imported pharmaceutical products within Latvia.

Quality & Labeling

SIA "magnipharma", — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SIA "magnipharma" focuses its product strategy on antiviral and HIV medications, specifically importing Sofosbuvir and Velpatasvir. This focus aligns with the global demand for effective treatments for hepatitis C and HIV, reflecting a strategic decision to address significant public health needs. The company's import data indicates a balanced investment in these products, with each accounting for $150K in imports, suggesting a commitment to providing comprehensive antiviral therapies to the Latvian market.

2Sourcing Profile

SIA "magnipharma" employs a sourcing strategy that emphasizes the import of generic antiviral medications, particularly Sofosbuvir and Velpatasvir, from India. This approach allows the company to offer cost-effective treatment options while maintaining a focus on quality. The limited number of formulations imported suggests a streamlined procurement process, potentially reducing operational complexities. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for SIA "magnipharma"'s sourcing needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to SIA "magnipharma",

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Latvian market by partnering with SIA "magnipharma". The company's current sourcing strategy, which relies on a single supplier for a limited product range, indicates potential gaps that new suppliers could fill. To capitalize on this opportunity, Indian exporters should ensure compliance with EU GMP standards, obtain the necessary import licenses, and meet the labeling and quality requirements set by Latvian authorities.

2Requirements & Qualifications

Indian exporters seeking to supply SIA "magnipharma" and enter the Latvian market must obtain an import license from the State Agency of Medicines. This requires submitting an application with detailed product information, including manufacturing descriptions and clinical trial results. Products must comply with EU GMP standards, and labeling must be in the Latvian language, providing clear information on usage, dosage, and potential side effects. Additionally, serialization may be required to enhance product traceability and prevent counterfeiting.

3How to Approach

Frequently Asked Questions — SIA "magnipharma",

What products does SIA "magnipharma", import from India?

SIA "magnipharma", imports 2 pharmaceutical products across 1 categories. Top imports: Sofosbuvir ($150.0K), Velpatasvir ($150.0K).

Who supplies pharmaceuticals to SIA "magnipharma", from India?

SIA "magnipharma", sources from 1 verified Indian suppliers. The primary supplier is Euro Lifecare Private Limited (100.0% of imports, $50.0K).

What is SIA "magnipharma",'s total pharmaceutical import value?

SIA "magnipharma",'s total pharmaceutical import value from India is $300.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SIA "magnipharma", focus on?

SIA "magnipharma", imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full SIA "magnipharma", Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.